Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia

Treatment Resistant Schizophrenia Clinical Trial

Official title:
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial

Status Recruiting

Clinical Trial Summary

Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist. In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%. Numerous augmentation agent have been tried which includes antipsychotics, anticonvulsants, antidepressants and NMDA antagonist. The NMDA antagonist such as Riluzole and Memantine have shown good efficacy in TRS. Therefore we are evaluating NMDA antagonist, dextromethorphan in TRS. The dextromethorphan or placebo will be administered along with clozapine in TRS patients. The study is randomized double blind placebo controlled group sequential trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Schizophrenia
Treatment Resistant Schizophrenia

Clinical Trial Details

NCT number	NCT05944510
Study type	Interventional
Source	All India Institute of Medical Sciences, Bhubaneswar
Contact	RITUPARNA MAITI, M.D.
Phone	9438884191
Email	pharm_rituparna@aiimsbhubaneswar.edu.in
Status	Recruiting
Phase	Phase 4
Start date	August 31, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03807882` - Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia	Phase 4
Not yet recruiting	`NCT06456983` - Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial	N/A
Not yet recruiting	`NCT06361160` - Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation	N/A